Alembic Pharma plans to get upto Rs 500 crore through NCDs
New Delhi: Drug firm Alembic Pharma on Thursday said it plans to raise up to Rs 500 crore through issue of non-convertible debentures (NCDs) on private placement basis.
The company's board of directors on Thursday approved the issue of unsecured listed redeemable NCDs of up to Rs 500 crore on private placement basis under a shelf disclosure document in multiple tranches, Alembic Pharmaceuticals said in a filing to the BSE.
The board also constituted NCD Committee for issue and allotment of NCDs, it added.
The company, however, did not disclose what it intends to do with the raised money.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd